Novo Nordisk is the latest insulin manufacturer to step in during the pandemic. Earlier this month, Eli Lilly announced that it would allow anyone with commercial health insurance or without health insurance to refill their insulin prescriptions for a $35 co-pay.
Insulin prices are notoriously high
Insulin costs between $2.28 and $3.42 for drug makers to manufacture, yet people with diabetes pay hundreds of dollars for the lifesaving drug.
And though little has changed about the way insulin is produced, prices have skyrocketed — some more than tripling over the past 10 years. As a result, as many as one in four people who take insulin skip doses because they cannot afford the medication that is keeping them alive.
To combat rising prices, lawmakers across the US have begun a push to cap costs. Colorado, Illinois and New Mexico have passed legislation to cap insulin co-pays, while more than a dozen others are considering similar bills.
Last year, executives from Novo Nordisk, Eli Lilly and Sanofi — the country’s leading insulin manufacturers — were ordered to testify on Capitol Hill regarding the rising prices of their drugs.
More than 30 million people in the United States — nearly one in every 10 Americans — have diabetes, according to the US Centers for Disease Control and Prevention. Another estimated 84 million are prediabetic and could require insulin later in life.
This content was originally published here.